US 12,134,660 B2
Anti-age antibodies for treating inflammation and auto-immune disorders
Lewis S. Gruber, Chicago, IL (US)
Assigned to Siwa Corporation, Chicago, IL (US)
Filed by SIWA Corporation, Chicago, IL (US)
Filed on Jan. 31, 2020, as Appl. No. 16/779,369.
Application 16/779,369 is a continuation of application No. 15/511,731, granted, now 10,584,180, previously published as PCT/US2015/050154, filed on Sep. 15, 2015.
Claims priority of provisional application 62/053,018, filed on Sep. 19, 2014.
Prior Publication US 2020/0231706 A1, Jul. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 16/24 (2006.01); C07K 16/44 (2006.01)
CPC C07K 16/44 (2013.01) [C07K 16/241 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. A method of treating inflammation or autoimmune disorders, comprising administering an antibody that binds to an AGE-modified protein on a cell.